Skip to main content
SpringerLink
Log in
Book cover

Managing Infections in Patients With Hematological Malignancies pp 113–134Cite as

Fungal and Parasitic Infections

  • Chapter
  • First Online:

  • 627 Accesses

Part of the book series: Contemporary Hematology ((CH))

Abstract

Fungal infections have emerged as major causes of morbidity and mortality among patients with hematological malignancies (Int J Antimicrob Agents 31:193–197, 2008). Although several new antifungal agents have become available for clinical use in the past few years, mortality from fungal infections remains above 20%. Advances in the management of hematological malignancies, including use of more aggressive regimens and expansion of the range of potential recipients to include patients who had previously not been considered for such treatments (e.g., elderly patients or patients with particular types of comorbid conditions), have led to increases in the number of patients at risk for invasive fungal infections (IFIs), as well as potentially more severe suppression of immune function (Int J Antimicrob Agents 31:193–197, 2008).

Remarkable advances in systemic antifungal therapy have occurred in the last decade, offering more options for the treatment of IFI. This chapter will focus on the management of these infections, as well as parasitic diseases that are occasionally seen in this immunocompromised population.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Maschmeyer G, Haas A (2008) The epidemiology and treatment of infections in cancer patients. Int J Antimicrob Agents 31:193–197

    Article  PubMed  CAS  Google Scholar 

  2. Garey KW, Rege M, Pai MP, Mingo DE, Suda KJ, Turpin RS, Bearden DT (2006) Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin Infect Dis 43(1):25–31

    Article  PubMed  CAS  Google Scholar 

  3. Morrell M, Fraser VJ, Kollef MH (2005) Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother 49(9):3640–3645

    Article  PubMed  CAS  Google Scholar 

  4. Wingard JR (2007) New approaches to invasive fungal infections in acute leukemia and hematopoietic stem cell transplant patients. Best Pract Res Clin Haematol 20(1):99–107

    Article  PubMed  Google Scholar 

  5. Segal BH, Almyroudis NG, Battiwalla M, Herbrecht R, Perfect JR, Walsh TJ, Wingard JR (2007) Prevention and early treatment of invasive fungal infection in patients with cancer and neutropenia and in stem cell transplant recipients in the era of newer broad-spectrum antifungal agents and diagnostic adjuncts. Clin Infect Dis 44(3):402–409

    Article  PubMed  Google Scholar 

  6. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E (2004) Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 10(Suppl 1):48–66

    Article  PubMed  Google Scholar 

  7. Bouza E, Munoz P (2004) Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect 10(Suppl 1):76–85

    Article  PubMed  Google Scholar 

  8. Alvarez M, Lopez Ponga B, Rayon C, Garcia Gala J, Roson Porto MC, Gonzalez M, Martinez-Suarez JV, Rodriguez-Tudela JL (1995) Nosocomial outbreak caused by Scedosporium prolificans (inflatum): four fatal cases in leukemic patients. J Clin Microbiol 33(12):3290–3295

    PubMed  CAS  Google Scholar 

  9. Matsue K, Uryu H, Koseki M, Asada N, Takeuchi M (2006) Breakthrough trichosporonosis in patients with hematologic malignancies receiving micafungin. Clin Infect Dis 42(6):753–757

    Article  PubMed  CAS  Google Scholar 

  10. Marr KA, Carter RA, Crippa F, Wald A, Corey L (2002) Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 34(7):909–917

    Article  PubMed  Google Scholar 

  11. Marr KA, Seidel K, White TC, Bowden RA (2000) Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 181(1):309–316

    Article  PubMed  CAS  Google Scholar 

  12. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R (1991) Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325(18):1274–1277

    Article  PubMed  CAS  Google Scholar 

  13. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB (2004) Nosocomial bloodstream infections in US hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis 39(3):309–317

    Article  PubMed  Google Scholar 

  14. Almirante B, Rodriguez D, Park BJ, Cuenca-Estrella M, Planes AM, Almela M, Mensa J, Sanchez F, Ayats J, Gimenez M et al (2005) Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003. J Clin Microbiol 43(4):1829–1835

    Article  PubMed  Google Scholar 

  15. Pfaller MA, Diekema DJ, Procop GW, Rinaldi MG (2007) Multicenter comparison of the VITEK 2 yeast susceptibility test with the CLSI broth microdilution reference method for testing fluconazole against Candida spp. J Clin Microbiol 45(3):796–802

    Article  PubMed  CAS  Google Scholar 

  16. Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, Weber SG (2005) Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother 49(11):4555–4560

    Article  PubMed  CAS  Google Scholar 

  17. Malani A, Hmoud J, Chiu L, Carver PL, Bielaczyc A, Kauffman CA (2005) Candida glabrata fungemia: experience in a tertiary care center. Clin Infect Dis 41(7):975–981

    Article  PubMed  Google Scholar 

  18. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S (1997) The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 24(6):1122–1128

    Article  PubMed  CAS  Google Scholar 

  19. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Calandra TF, Edwards JE, Filler AG et al (2009) Clinical Practice Guidelines for the Management of Candidiasis:2009 Update by the Infectious Diseases Society of America. Clin Infect Dis 48 (1 March): 503–535

    Article  PubMed  Google Scholar 

  20. Hazen KC, Baron EJ, Colombo AL, Girmenia C, Sanchez-Sousa A, del Palacio A, de Bedout C, Gibbs DL (2003) Comparison of the susceptibilities of Candida spp.to fluconazole and voriconazole in a 4-year global evaluation using disk diffusion. J Clin Microbiol 41(12):5623–5632

    Article  PubMed  CAS  Google Scholar 

  21. Myoken Y, Kyo T, Kohara T, Fujihara M, Sugata T, Mikami Y (2003) Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia. Clin Infect Dis 36(11):1496–1497

    Article  PubMed  Google Scholar 

  22. Ostrosky-Zeichner L, Kontoyiannis D, Raffalli J, Mullane KM, Vazquez J, Anaissie EJ, Lipton J, Jacobs P, van Rensburg JH, Rex JH et al (2005) International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur J Clin Microbiol Infect Dis 24(10):654–661

    Article  PubMed  CAS  Google Scholar 

  23. Rex JH, Bennett JE, Sugar AM, Pappas PG, van der Horst CM, Edwards JE, Washburn RG, Scheld WM, Karchmer AW, Dine AP et al (1994) A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute. N Engl J Med 33(20):1325–1330

    Article  Google Scholar 

  24. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO, Williams T, Kontoyiannis DP, Karl CL, Bodey GP (1996) Management of invasive candidal infections: results of a prospective, randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis 23(5):964–972

    Article  PubMed  CAS  Google Scholar 

  25. Mora-Duarte J, Betts R, Rotstein C, Colombo AL, Thompson-Moya L, Smietana J, Lupinacci R, Sable C, Kartsonis N, Perfect J (2002) Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 347(25):2020–2029

    Article  PubMed  CAS  Google Scholar 

  26. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, Vazquez JA, Dupont BF, Horn DL, Ostrosky-Zeichner L et al (2007) Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 45(7):883–893

    Article  PubMed  CAS  Google Scholar 

  27. Aperis G, Myriounis N, Spanakis EK, Mylonakis E (2006) Developments in the treatment of candidiasis: more choices and new challenges. Expert Opin Investig Drugs 15(11):1319–1336

    Article  PubMed  CAS  Google Scholar 

  28. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T (2004) Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother 48(6):2021–2024

    Article  PubMed  CAS  Google Scholar 

  29. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D, Betts R, Wible M, Goldstein BP, Schranz J et al (2007) Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 356(24):2472–2482

    Article  PubMed  CAS  Google Scholar 

  30. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT et al (2007) Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 356(4):348–359

    Article  PubMed  CAS  Google Scholar 

  31. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N et al (2007) Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 356(4):335–347

    Article  PubMed  CAS  Google Scholar 

  32. Cota J, Carden M, Graybill JR, Najvar LK, Burgess DS, Wiederhold NP (2006) In vitro pharmacodynamics of anidulafungin and caspofungin against Candida glabrata isolates, including strains with decreased caspofungin susceptibility. Antimicrob Agents Chemother 50(11):3926–3928

    Article  PubMed  CAS  Google Scholar 

  33. Pfaller MA, Messer SA, Hollis RJ, Jones RN, Diekema DJ (2002) In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6, 970 clinical isolates of Candida spp. Antimicrob Agents Chemother 46(6):1723–1727

    Article  PubMed  CAS  Google Scholar 

  34. Ostrosky-Zeichner L, Rex JH, Pappas PG, Hamill RJ, Larsen RA, Horowitz HW, Powderly WG, Hyslop N, Kauffman CA, Cleary J et al (2003) Antifungal susceptibility survey of 2, 000 bloodstream Candida isolates in the United States. Antimicrob Agents Chemother 47(10):3149–3154

    Article  PubMed  CAS  Google Scholar 

  35. Pfaller MA, Diekema DJ, Messer SA, Boyken L, Hollis RJ (2003) Activities of fluconazole and voriconazole against 1, 586 recent clinical isolates of Candida species determined by Broth microdilution, disk diffusion, and Etest methods: report from the ARTEMIS Global Antifungal Susceptibility Program, 2001. J Clin Microbiol 41(4):1440–1446

    Article  PubMed  CAS  Google Scholar 

  36. Tortorano AM, Peman J, Bernhardt H, Klingspor L, Kibbler CC, Faure O, Biraghi E, Canton E, Zimmermann K, Seaton S et al (2004) Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study. Eur J Clin Microbiol Infect Dis 23(4):317–322

    Article  PubMed  CAS  Google Scholar 

  37. Dimopoulos G, Karabinis A, Samonis G, Falagas ME (2007) Candidemia in immunocompromised and immunocompetent critically ill patients: a prospective comparative study. Eur J Clin Microbiol Infect Dis 26(6):377–384

    Article  PubMed  CAS  Google Scholar 

  38. Nucci M, Colombo AL (2007) Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals. Diagn Microbiol Infect Dis 58(1):77–82

    Article  PubMed  CAS  Google Scholar 

  39. Vigouroux S, Morin O, Moreau P, Harousseau JL, Milpied N (2006) Candidemia in patients with hematologic malignancies: analysis of 7 years’ experience in a single center. Haematologica 91(5):717–718

    PubMed  Google Scholar 

  40. Vandeputte P, Larcher G, Berges T, Renier G, Chabasse D, Bouchara JP (2005) Mechanisms of azole resistance in a clinical isolate of Candida tropicalis. Antimicrob Agents Chemother 49(11):4608–4615

    Article  PubMed  CAS  Google Scholar 

  41. Myoken Y, Kyo T, Fujihara M, Sugata T, Mikami Y (2004) Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies. Haematologica 89(3):378–380

    PubMed  Google Scholar 

  42. Tortorano AM, Rigoni AL, Biraghi E, Prigitano A, Viviani MA (2003) The European Confederation of Medical Mycology (ECMM) survey of candidaemia in Italy: antifungal susceptibility patterns of 261 non-albicans Candida isolates from blood. J Antimicrob Chemother 52(4):679–682

    Article  PubMed  CAS  Google Scholar 

  43. Yang YL, Ho YA, Cheng HH, Ho M, Lo HJ (2004) Susceptibilities of Candida species to amphotericin B and fluconazole: the emergence of fluconazole resistance in Candida tropicalis. Infect Control Hosp Epidemiol 25(1):60–64

    Article  PubMed  CAS  Google Scholar 

  44. Forrest GN, Weekes E, Johnson JK (2008) Increasing incidence of Candida parapsilosis candidemia with caspofungin usage. J Infect 56:126–129

    Article  PubMed  Google Scholar 

  45. Sims CR, Ostrosky-Zeichner L, Rex JH (2005) Invasive candidiasis in immunocompromised hospitalized patients. Arch Med Res 36(6):660–671

    Article  PubMed  Google Scholar 

  46. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley S, Brass C, Vazquez JA, Chapman SW, Horowitz HW et al (2003) A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericinB as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis 36(10):1221–1228

    Article  PubMed  CAS  Google Scholar 

  47. Anaissie EJ, Stratton SL, Dignani MC, Lee CK, Summerbell RC, Rex JH, Monson TP, Walsh TJ (2003) Pathogenic molds (including Aspergillus species) in hospital water distribution systems: a 3-year prospective study and clinical implications for patients with hematologic malignancies. Blood 101(7):2542–2546

    Article  PubMed  CAS  Google Scholar 

  48. Anaissie EJ, Costa SF (2001) Nosocomial aspergillosis is waterborne. Clin Infect Dis 33(9):1546–1548

    Article  PubMed  CAS  Google Scholar 

  49. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, Bennett JE, Walsh TJ, Patterson TF, Pankey GA (2000) Practice guidelines for diseases caused by Aspergillus. Infectious Diseases Society of America. Clin Infect Dis 30(4):696–709

    Article  PubMed  CAS  Google Scholar 

  50. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A et al (2007) Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). Clin Infect Dis 44(10):1289–1297

    Article  PubMed  CAS  Google Scholar 

  51. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Segal BH, Steinbach WJ, Stevens DA et al (2008) Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 46(3):327–360

    Article  PubMed  CAS  Google Scholar 

  52. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O et al (2002) Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 347(6):408–415

    Article  PubMed  CAS  Google Scholar 

  53. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A et al (2004) Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 39(11):1563–1571

    Article  PubMed  CAS  Google Scholar 

  54. Candoni A, Mestroni R, Damiani D, Tiribelli M, Michelutti A, Silvestri F, Castelli M, Viale P, Fanin R (2005) Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. Eur J Haematol 75(3):227–233

    Article  PubMed  CAS  Google Scholar 

  55. Kontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II (2003) Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer 98(2):292–299

    Article  PubMed  CAS  Google Scholar 

  56. Singh N, Limaye AP, Forrest G, Safdar N, Munoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P et al (2006) Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 81(3):320–326

    Article  PubMed  CAS  Google Scholar 

  57. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L (2004) Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 39(6):797–802

    Article  PubMed  CAS  Google Scholar 

  58. Krcmery V Jr, Mateicka F, Kunova A, Spanik S, Gyarfas J, Sycova Z, Trupl J (1999) Hematogenous trichosporonosis in cancer patients: report of 12 cases including 5 during prophylaxis with itraconazol. Support Care Cancer 7(1):39–43

    Article  PubMed  Google Scholar 

  59. Walsh TJ, Melcher GP, Rinaldi MG, Lecciones J, McGough DA, Kelly P, Lee J, Callender D, Rubin M, Pizzo PA (1990) Trichosporon beigelii, an emerging pathogen resistant to amphotericin B. J Clin Microbiol 28(7):1616–1622

    PubMed  CAS  Google Scholar 

  60. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O’Brien S, Verstovsek S, Faderl S, Zhou X, Raad II et al (2006) Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother 50(1):143–147

    Article  PubMed  CAS  Google Scholar 

  61. Girmenia C, Pagano L, Martino B, D’Antonio D, Fanci R, Specchia G, Melillo L, Buelli M, Pizzarelli G, Venditti M et al (2005) Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 43(4):1818–1828

    Article  PubMed  Google Scholar 

  62. Anaissie E, Gokaslan A, Hachem R, Rubin R, Griffin G, Robinson R, Sobel J, Bodey G (1992) Azole therapy for trichosporonosis: clinical evaluation of eight patients, experimental therapy for murine infection, and review. Clin Infect Dis 15(5):781–787

    Article  PubMed  CAS  Google Scholar 

  63. Walsh TJ, Lee JW, Melcher GP, Navarro E, Bacher J, Callender D, Reed KD, Wu T, Lopez-Berestein G, Pizzo PA (1992) Experimental Trichosporon infection in persistently granulocytopenic rabbits: implications for pathogenesis, diagnosis, and treatment of an emerging opportunistic mycosis. J Infect Dis 166(1):121–133

    Article  PubMed  CAS  Google Scholar 

  64. Fournier S, Pavageau W, Feuillhade M, Deplus S, Zagdanski AM, Verola O, Dombret H, Molina JM (2002) Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 21(12):892–896

    PubMed  CAS  Google Scholar 

  65. Paphitou NI, Ostrosky-Zeichner L, Paetznick VL, Rodriguez JR, Chen E, Rex JH (2002) In vitro antifungal susceptibilities of Trichosporon species. Antimicrob Agents Chemother 46(4):1144–1146

    Article  PubMed  CAS  Google Scholar 

  66. Serena C, Gilgado F, Marine M, Pastor FJ, Guarro J (2006) Efficacy of voriconazole in a guinea pig model of invasive trichosporonosis. Antimicrob Agents Chemother 50(6):2240–2243

    Article  PubMed  CAS  Google Scholar 

  67. Asada N, Uryu H, Koseki M, Takeuchi M, Komatsu M, Matsue K (2006) Successful treatment of breakthrough Trichosporon asahii fungemia with voriconazole in a patient with acute myeloid leukemia. Clin Infect Dis 43(4):e39–e41

    Article  PubMed  Google Scholar 

  68. Kauffman CA (2004) Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 39(4):588–590

    Article  PubMed  Google Scholar 

  69. Kontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ et al (2005) Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: a case-control observational study of 27 recent cases. J Infect Dis 191(8):1350–1360

    Article  PubMed  Google Scholar 

  70. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaufele RL, Sein M, Sein T, Chiou CC, Chu JH et al (2005) Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 41(5):634–653

    Article  PubMed  Google Scholar 

  71. van Burik JA, Hare RS, Solomon HF, Corrado ML, Kontoyiannis DP (2006) Posaconazole is effective as salvage therapy in zygomycosis: a retrospective summary of 91 cases. Clin Infect Dis 42(7):e61–e65

    Article  PubMed  Google Scholar 

  72. Spellberg B, Fu Y, Edwards JE Jr, Ibrahim AS (2005) Combination therapy with amphotericin B lipid complex and caspofungin acetate of disseminated zygomycosis in diabetic ketoacidotic mice. Antimicrob Agents Chemother 49(2):830–832

    Article  PubMed  CAS  Google Scholar 

  73. Pagano L, Fianchi L, Caramatti C, D’Antonio D, Melillo L, Caira M, Masini L, Todeschini G, Girmenia C, Martino B et al (2004) Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica 89(7):852–856

    PubMed  Google Scholar 

  74. Valero G, Graybill JR (1995) Successful treatment of cryptococcal meningitis with amphotericin B colloidal dispersion: report of four cases. Antimicrob Agents Chemother 39(11):2588–2590

    PubMed  CAS  Google Scholar 

  75. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O (2007) Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med 4(2):e21

    Article  PubMed  Google Scholar 

  76. Sepkowitz KA (2002) Opportunistic infections in patients with and patients without Acquired Immunodeficiency Syndrome. Clin Infect Dis 34(8):1098–1107

    Article  PubMed  Google Scholar 

  77. Roblot F, Le Moal G, Godet C, Hutin P, Texereau M, Boyer E, Prazuck T, Lacroix C, Souala MF, Raffi F et al (2003) Pneumocystis carinii pneumonia in patients with hematologic malignancies: a descriptive study. J Infect 47(1):19–27

    Article  PubMed  CAS  Google Scholar 

  78. Marty FM, Koo S, Bryar J, Baden LR (2007) (1→3)beta-d-glucan assay positivity in patients with Pneumocystis (carinii) jiroveci pneumonia. Ann Intern Med 147(1):70–72

    PubMed  Google Scholar 

  79. Madhi SA, Albrich W (2007) WHO guidelines for treatment of severe pneumonia. Lancet 370(9585):386–387

    Article  PubMed  Google Scholar 

  80. Sepkowitz KA (1992) Pneumocystis carinii pneumonia among patients with neoplastic disease. Semin Respir Infect 7(2):114–121

    PubMed  CAS  Google Scholar 

  81. Patel N, Koziel H (2004) Pneumocystis jiroveci pneumonia in adult patients with AIDS: treatment strategies and emerging challenges to antimicrobial therapy. Treat Respir Med 3(6):381–397

    Article  PubMed  CAS  Google Scholar 

  82. Israelski DM, Remington JS (1993) Toxoplasmosis in patients with cancer. Clin Infect Dis 17(Suppl 2):S423–S435

    Article  PubMed  Google Scholar 

  83. Chandrasekar PH, Momin F (1997) Disseminated toxoplasmosis in marrow recipients: a report of three cases and a review of the literature. Bone Marrow Transplant Team. Bone Marrow Transplant 19(7):685–689

    Article  PubMed  CAS  Google Scholar 

  84. Pagano L, Trape G, Putzulu R, Caramatti C, Picardi M, Nosari A, Cinieri S, Caira M, Del Favero A (2004) Toxoplasma gondii infection in patients with hematological malignancies. Ann Hematol 83(9):592–595

    Article  PubMed  Google Scholar 

  85. Mele A, Paterson PJ, Prentice HG, Leoni P, Kibbler CC (2002) Toxoplasmosis in bone marrow transplantation: a report of two cases and systematic review of the literature. Bone Marrow Transplant 29(8):691–698

    Article  PubMed  CAS  Google Scholar 

  86. Byrd JC, Peterson B, Piro L, Saven A, Vardiman JW, Larson RA, Schiffer C (2003) A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211. Leukemia 17(2):323–327

    Article  PubMed  CAS  Google Scholar 

  87. Mechain B, Garin YJ, Robert-Gangneux F, Dupouy-Camet J, Derouin F (2000) Lack of utility of specific immunoglobulin G antibody avidity for serodiagnosis of reactivated toxoplasmosis in immunocompromised patients. Clin Diagn Lab Immunol 7(4):703–705

    PubMed  CAS  Google Scholar 

  88. Derouin F, Devergie A, Auber P, Gluckman E, Beauvais B, Garin YJ, Lariviere M (1992) Toxoplasmosis in bone marrow-transplant recipients: report of seven cases and review. Clin Infect Dis 15(2):267–270

    Article  PubMed  CAS  Google Scholar 

  89. Lewthwaite P, Gill GV, Hart CA, Beeching NJ (2005) Gastrointestinal parasites in the immunocompromised. Curr Opin Infect Dis 18(5):427–435

    Article  PubMed  Google Scholar 

  90. Vijayan VK (2007) How to diagnose and manage common parasitic pneumonias. Curr Opin Pulm Med 13(3):218–224

    Article  PubMed  Google Scholar 

  91. Al-Hasan MN, McCormick M, Ribes JA (2007) Invasive enteric infections in hospitalized patients with underlying strongyloidiasis. Am J Clin Pathol 128(4):622–627

    Article  PubMed  Google Scholar 

  92. Keiser PB, Nutman TB (2004) Strongyloides stercoralis in the Immunocompromised Population. Clin Microbiol Rev 17(1):208–217

    Article  PubMed  Google Scholar 

  93. Wehner JH, Kirsch CM (1997) Pulmonary manifestations of strongyloidiasis. Semin Respir Infect 12(2):122–129

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematologic Malignancies Supportive Care Program, Department of Leukemia, M.D. Anderson Cancer Center, Houston, TX, USA

    Gloria Mattiuzzi M.D. (Leader)

  2. Department of Medicine and Epidemiology, Division of Infectious Diseases, University of Texas Medical School at Houston, Houston, TX, USA

    Luis Ostrosky-Zeichner M.D., F.A.C.P., F.I.D.S.A.

Authors
  1. Gloria Mattiuzzi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Luis Ostrosky-Zeichner M.D., F.A.C.P., F.I.D.S.A.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gloria Mattiuzzi M.D. .

Editor information

Editors and Affiliations

  1. School of Medicine, University of Maryland, S. Greene St. 22, Baltimore, 21201, U.S.A.

    Michael Kleinberg

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Humana Press

About this chapter

Cite this chapter

Mattiuzzi, G., Ostrosky-Zeichner, L. (2009). Fungal and Parasitic Infections. In: Kleinberg, M. (eds) Managing Infections in Patients With Hematological Malignancies. Contemporary Hematology. Humana Press. https://doi.org/10.1007/978-1-59745-415-5_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-415-5_4

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-986-4

  • Online ISBN: 978-1-59745-415-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation